The integrin alphavbeta6 is a receptor for the extracellular matrix proteins fibronectin and tenascin. This receptor is highly expressed in the epithelium of the respiratory tract and the skin during development, after injury or inflammation, and in malignant tumors, but is not expressed at either site in normal, healthy adults. In vitro, heterologous expression of alphavbeta6 in tumor cells increases cell adhesion to fibronectin and tenascin and also increases the capacity of these cells to proliferate. However, nothing is known about what role, if any, this receptor plays in vivo. To examine the in vivo function of alphavbeta6, we are producing mice that are deficient in receptor expression using standard homologous recombination in embryonic stem cells. In parallel, we are producing mice that overexpress either functional receptor, or a mutant version engineered to be incapable of binding ligand, under the control of highly active promoters that target expression to the airway epithelium (CC10), to alveolar type II cells and bronchiolar epithelium (SPC), or to basal keratinocytes (K14). Examination of the growth and development of mice deficient in beta6 protein should provide important clues to what role, if any, this receptor plays in epithelial differentiation and organogenesis. In addition, we propose to produce cutaneous wounds and respiratory epithelial injuries in these mice to determine the role of alphavbeta6 in epithelial repair in the lungs and skin. We also propose to examine the effects of overexpression of intact or mutant beta6, and of knockout of the beta6 gene, on the development of spontaneous and chemically-induced lung tumors. These studies should provide important information about the in vivo function of this integrin in lung (and cutaneous) development, in the repair of lung (and cutaneous) injury, and in the development, growth and/or progression of lung tumors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL053949-03
Application #
2378834
Study Section
Lung Biology and Pathology Study Section (LBPA)
Project Start
1995-04-01
Project End
2000-02-29
Budget Start
1997-03-01
Budget End
1998-02-28
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Mallavia, B; Liu, F; Sheppard, D et al. (2016) Inhibiting Integrin ?v?5 Reduces Ischemia-Reperfusion Injury in an Orthotopic Lung Transplant Model in Mice. Am J Transplant 16:1306-11
Reed, Nilgun I; Jo, Hyunil; Chen, Chun et al. (2015) The ?v?1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med 7:288ra79
Plaks, Vicki; Boldajipour, Bijan; Linnemann, Jelena R et al. (2015) Adaptive Immune Regulation of Mammary Postnatal Organogenesis. Dev Cell 34:493-504
Xu, Pinglong; Bailey-Bucktrout, Samantha; Xi, Ying et al. (2014) Innate antiviral host defense attenuates TGF-? function through IRF3-mediated suppression of Smad signaling. Mol Cell 56:723-37
Erle, David J; Sheppard, Dean (2014) The cell biology of asthma. J Cell Biol 205:621-31
Henderson, Neil C; Sheppard, Dean (2013) Integrin-mediated regulation of TGF? in fibrosis. Biochim Biophys Acta 1832:891-6
Su, George; Atakilit, Amha; Li, John T et al. (2013) Effective treatment of mouse sepsis with an inhibitory antibody targeting integrin *v*5. Crit Care Med 41:546-53
Friedman, Scott L; Sheppard, Dean; Duffield, Jeremy S et al. (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5:167sr1
Sheppard, Dean (2013) ROCKing pulmonary fibrosis. J Clin Invest 123:1005-6
Henderson, Neil C; Arnold, Thomas D; Katamura, Yoshio et al. (2013) Targeting of ?v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19:1617-24

Showing the most recent 10 out of 55 publications